No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
714 |
4. Check minimum number of eventsNone |
714 |
5. Include endpointsNone |
714 |
6. Filter based on genotype QC (FinnGen only) |
714 |
Control definitions (FinnGen only)
- Control exclude
- H7_OPTNERVE
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- H47
- Name in latin
- Morbositates nervi optici non alibi classificatae
Similar endpoints
↥List of similar endpoints to
Disorders of optic nerve, not elsewhere classified
based on the number of shared cases.
Similar with more cases:
- Other disorders of optic [2nd] nerve and visual pathways
- Disorders of optic nerve and visual pathways
- Diseases of the eye and adnexa
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 5048 | 2489 | 2516 |
| Only index persons | 4410 | 2212 | 2198 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.07 | 0.07 | 0.07 |
| Only index persons | 0.08 | 0.08 | 0.08 |
| Median age at first event (years) | |||
| Whole population | 62.97 | 63.63 | 62.38 |
| Only index persons | 62.67 | 63.16 | 62.18 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 714 | 362 | 352 |
| Unadjusted period prevalence (%) | 0.14 | 0.12 | 0.16 |
| Median age at first event (years) | 61.87 | 59.28 | 64.52 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 635
- Matched controls
- 6347
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H47.0
ICD-10 Finland
Disorders of optic nerve, not elsewhere classified
+∞
323.0
594
*
XCK00
NOMESCO Finland
Perimetry
16.4
125.8
217
195
H47.1
ICD-10 Finland
Papilloedema, unspecified
+∞
110.7
103
*
H46
ICD-10 Finland
Optic neuritis
1057.7
95.5
91
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.5
47.7
204
610
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
6.0
47.5
144
294
XCK10
NOMESCO Finland
Photography of fundus of eye
5.5
47.3
158
363
H47.2
ICD-10 Finland
Optic atrophy
+∞
46.4
44
*
H53.4
ICD-10 Finland
Visual field defects
16.7
44.9
73
49
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
10.0
36.9
76
85
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
47.1
36.4
44
10
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
5.9
36.2
109
216
XCD10
NOMESCO Finland
Electrophysiological examination of eye
11.8
36.1
68
64
XCW99
NOMESCO Finland
Other investigative procedure of eye
4.3
35.6
149
422
37799
ICD-8 Finland
Other diseases of retina and optic nerve, Unspecified
+∞
34.7
33
*
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
6.2
34.3
98
181
H47.3
ICD-10 Finland
Other disorders of optic disc
+∞
31.5
30
*
H53.1
ICD-10 Finland
Subjective visual disturbances
5.6
29.0
90
183
G35
ICD-10 Finland
Multiple sclerosis
25.2
27.3
38
16
CS424
NOMESCO Finland
Visual field testing with Goldmann perimetry
23.8
25.5
36
16
CS494
NOMESCO Finland
Other visual field testing
10.1
24.4
49
52
TAB00
NOMESCO Finland
Lumbar puncture
6.1
24.2
68
122
CA1CM
NOMESCO Finland
Eye and orbita extensive MRI examination with 3 Tesla magnet
119.1
21.7
23
*
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
45.0
21.5
26
6
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
35.1
21.3
27
8
109
Kela drug reimbursment
Multiple sclerosis
31.2
20.7
27
9
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
7.7
20.1
47
65
D32.02
ICD-10 Finland
Benign tumor of the meninges at the base of the brain
27.0
19.3
26
10
PAW37
NOMESCO Finland
Biopsy of temporal artery
20.1
18.3
27
14
H53.9
ICD-10 Finland
Visual disturbance, unspecified
6.2
16.3
44
75
Z96.1
ICD-10 Finland
Presence of intraocular lens
2.8
16.1
117
480
M31.5
ICD-10 Finland
Giant cell arteritis with polymyalgia rheumatica
11.6
15.9
29
26
CA1BG
NOMESCO Finland
Eye and orbita MRI examination with high intensity magnet
87.2
15.6
17
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.0
15.5
314
2088
N86
ICPC
Multiple sclerosis
82.0
14.6
16
*
AA1AD
NOMESCO Finland
CT of head and brain
2.2
14.5
185
1012
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
8.7
14.1
30
36
XCD20
NOMESCO Finland
Photoangiography of eye
8.4
13.4
29
36
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.2
13.3
74
253
G93.2
ICD-10 Finland
Benign intracranial hypertension
+∞
12.5
12
*
CS434
NOMESCO Finland
Visual field testing with Humphrey automated perimetry
6.3
12.3
32
53
CS5Z4
NOMESCO Finland
Specialised imaging for glaucoma
6.3
11.9
31
51
H34.1
ICD-10 Finland
Central retinal artery occlusion
12.9
11.7
20
16
R51.80
ICD-10 Finland
Headache
2.4
11.6
104
475
L03AX13
ATC
glatiramer acetate; parenteral
122.1
11.5
12
*
L03AB07
ATC
interferon beta-1a; parenteral
25.5
11.2
15
6
3774A
ICD-9 Finland
Disorders of optic nerve and visual pathways, Other disorders of optic nerve
+∞
10.4
10
*
S01EC01
ATC
acetazolamide; systemic
5.6
10.2
29
54
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
17.0
9.9
15
9
L04AX07
ATC
dimethyl fumarate; oral
55.8
9.7
11
*
H02AB06
ATC
prednisolone; systemic
1.7
9.1
299
2195
H54.4
ICD-10 Finland
Blindness, monocular
37.2
9.0
11
*
PA6DE
NOMESCO Finland
Neck artery ultrasound examination with Doppler method
3.1
8.9
48
163
H54.2
ICD-10 Finland
Moderate visual impairment, binocular
9.7
8.8
17
18
PA6BD
NOMESCO Finland
Extensive CT of neck arteries
3.3
8.7
43
137
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
11.8
8.6
15
13
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.2
8.6
87
420
H40.0
ICD-10 Finland
Glaucoma suspect
2.7
8.6
59
235
CA1DG
NOMESCO Finland
Eye and orbita very extensive MRI examination with high intensity magnet
91.2
8.4
9
*
H47.7
ICD-10 Finland
Disorder of visual pathways, unspecified
+∞
8.3
8
*
H54.1
ICD-10 Finland
Severe visual impairment, binocular
+∞
8.3
8
*
CS3P4
NOMESCO Finland
Optic nerve head stereophotography
7.0
8.1
19
28
WX408
NOMESCO Finland
General anesthesy, balanced
1.8
8.0
175
1130
ZXA10
NOMESCO Finland
Bilateral
1.9
8.0
132
778
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
7.1
7.8
18
26
F05
ICPC
Visual disturbance other
4.2
7.8
28
69
H40.11
ICD-10 Finland
Low pressure glaucoma
4.9
7.5
23
48
H34.8
ICD-10 Finland
Other retinal vascular occlusions
4.4
7.4
25
58
H25.1
ICD-10 Finland
Senile nuclear cataract
1.7
7.3
176
1166
CK2A4
NOMESCO Finland
Autofluorescence imaging of ocular fundus
30.4
7.2
9
*
B01AC04
ATC
clopidogrel; oral
1.9
7.2
112
647
H53.8
ICD-10 Finland
Other visual disturbances
6.1
7.1
18
30
CJE20
NOMESCO Finland
Phakoemulsification with implantation of artificial lens in posterior chamber
1.6
7.0
202
1408
A02BC02
ATC
pantoprazole; systemic
1.6
6.9
396
3260
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
2.7
6.9
44
168
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
6.8
6.8
16
24
114
Kela drug reimbursment
Glaucoma
2.3
6.8
64
301
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
2.6
6.8
47
188
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
1.9
6.7
108
627
L03AB08
ATC
interferon beta-1b; parenteral
70.5
6.4
7
*
164
Kela drug reimbursment
Fingolimod
+∞
6.3
6
*
H47
ICD-10 Finland
Other disorders of optic [2nd] nerve and visual pathways
+∞
6.3
6
*
A10AB05
ATC
insulin aspart; parenteral (insulins and analog. for injection, fast-acting)
2.3
6.2
53
237
WX892
NOMESCO Finland
Monitored bed care
2.3
6.2
55
248
N05CF01
ATC
zopiclone; oral
1.6
6.2
205
1467
S01ED51
ATC
timolol, combinations; ophthalmic
2.3
6.2
55
250
S01CA01
ATC
dexamethasone and antiinfectives; ophthalmic (ophth., corticosteroids and antiinfectives in comb.)
1.6
6.2
216
1567
XF400
NOMESCO Finland
ECG with 12 standard connections
1.8
6.2
104
612
TPH04
NOMESCO Finland
Cathetrisation of vein
1.7
6.1
129
819
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.5
6.0
248
1867
H3603, E113
ICD-10 Finland
NA
6.1
6.0
15
25
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
33
35
9.84
28.15
1.1
1.0
—
—
—
0
0
27
29
9.64
22.76
1.1
1.0
1.2
1.1
u/l
0.07
12
17
437
3004
2.17
21.88
9.8
7.1
1.2
1.2
mmol/l
0.76
374
2531
36
61
6.16
20.60
1.0
1.1
—
—
—
0
0
35
58
6.29
20.47
1.0
1.1
—
—
—
0
0
299
1832
2.09
19.64
2.4
2.1
217.4
242.1
u/l
0.17
280
1720
31
48
6.71
19.33
1.0
1.1
—
—
—
0
0
397
2748
2.00
18.09
8.5
6.3
1.2
1.2
mmol/l
1.09
369
2482
117
532
2.43
15.61
9.6
7.4
11.1
10.4
mmol/l
0.43
111
507
544
4350
2.05
14.85
6.0
4.1
14.0
12.8
mm/h
1.01
505
3974
461
3510
1.88
14.25
6.2
5.0
6.9
6.7
mmol/l
0.59
435
3292
149
786
2.13
13.85
8.6
5.6
1.1
1.0
mmol/l
1.23
144
724
366
2619
1.82
13.57
6.3
4.7
34.9
35.2
g/l
0.45
340
2435
28
56
5.16
13.46
1.2
1.2
—
—
—
0
0
444
3388
1.82
13.10
11.3
8.9
4.4
4.1
e9/l
1.29
399
2975
317
2194
1.80
12.95
4.1
3.3
—
—
—
0
0
42
125
3.51
12.10
1.5
1.3
22.7
992.1
e6/l
0.60
37
104
42
125
3.51
12.10
1.5
1.2
3.1
11.0
e6/l
0.78
35
101
549
4559
1.88
11.36
10.1
7.6
82.4
78.7
u/l
0.69
511
4260
326
2347
1.72
11.08
4.9
3.9
29.4
54.5
ng/l
1.05
246
1719
164
970
1.90
10.82
4.0
3.5
0.8
0.8
mmol/l
1.00
155
912
111
574
2.11
10.71
5.4
3.6
1.7
2.0
mmol/l
0.39
94
459
111
575
2.10
10.66
5.4
3.6
5.8
5.8
kpa
0.07
111
558
406
3142
1.68
10.22
7.3
6.3
12.2
11.5
umol/l
0.34
389
2977
103
527
2.12
10.20
2.6
3.2
64.6
66.6
g/l
1.91
95
479
157
948
1.84
9.60
2.6
2.0
31.1
29.6
s
0.77
150
922
95
485
2.11
9.44
4.1
2.9
4.6
4.4
kpa
0.61
95
468
242
1680
1.67
8.96
3.7
3.2
0.2
0.5
e6/l
2.81
186
1272
122
696
1.91
8.86
3.9
4.2
239.2
244.5
u/l
0.24
116
662
639
5754
2.05
8.13
23.7
15.3
24.9
24.7
mg/l
0.04
535
4587
316
2385
1.58
8.13
2.7
2.2
80.5
77.9
nmol/l
0.79
294
2104
471
3901
1.61
8.10
6.5
4.6
16.6
3698.6
e6/l
1.84
11
67
657
5992
2.21
7.84
26.3
17.9
139.6
139.7
mmol/l
0.30
644
5822
361
2826
1.56
7.81
5.0
3.8
0.0
0.0
estimate
0.00
61
541
657
6008
2.17
7.52
26.8
18.0
4.0
4.0
mmol/l
0.11
643
5828
156
1005
1.71
7.48
2.0
1.9
—
—
—
0
0
17
38
4.56
7.21
2.1
1.9
581.8
673.5
e6/l
—
6
15
158
1033
1.68
7.15
3.2
2.8
1.4
1.0
e6/l
0.53
87
600
358
2835
1.53
7.11
6.5
5.2
0.0
0.0
estimate
0.00
63
539
443
3675
1.54
7.07
3.9
3.1
54.4
50.9
u/l
0.34
416
3396
48
213
2.34
6.71
2.6
2.1
536.6
618.0
ug/l
0.09
43
199
360
2878
1.51
6.69
5.0
3.8
0.0
0.0
estimate
0.50
61
522
116
711
1.75
6.60
7.2
8.4
1.4
1.3
mmol/l
0.09
88
564
116
715
1.74
6.47
7.4
8.3
12.8
11.9
kpa
0.93
110
687
116
715
1.74
6.47
7.4
8.3
4.9
5.1
kpa
1.08
110
686
312
2442
1.49
6.31
3.6
2.7
133.9
138.5
ug/l
0.17
286
2232
132
850
1.68
6.27
3.9
2.4
22.0
22.5
%
0.15
111
723
184
1287
1.58
6.26
3.4
2.7
4.6
4.8
e6/l
0.13
168
1137
269
2051
1.50
6.14
3.8
3.4
2.3
2.4
mmol/l
0.07
244
1776
20
58
3.52
6.04
2.1
2.5
—
—
—
0
0
145
965
1.63
6.04
3.8
2.4
12.2
12.9
umol/l
0.65
136
892
249
1876
1.50
5.99
2.9
2.5
60.6
56.1
u/l
0.36
231
1739
13
27
4.89
5.99
1.5
2.2
101.0
89.6
umol/l
—
8
19
10
16
6.32
5.97
1.1
1.0
1879.4
1712.3
miu/ml
—
10
16
9
6
15.16
5.91
1.1
1.2
—
—
—
0
0
57
287
2.07
5.88
2.1
2.1
1.5
1.5
g/l
0.08
48
255
14
32
4.44
5.78
1.6
1.8
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
45
208
2.24
5.76
2.6
2.6
0.3
0.3
u/ml
0.32
28
117
39
170
2.37
5.70
1.3
1.6
—
—
—
0
0
214
1576
1.51
5.69
3.5
2.8
353.7
8491.7
umol/l
7.51
180
1345
40
177
2.33
5.66
1.8
1.5
0.9
0.1
iu/ml
0.41
11
37
28
104
2.76
5.65
1.5
1.4
—
—
—
0
0
658
6120
1.96
5.62
14.5
10.7
27.8
25.8
u/l
1.00
637
5875
112
712
1.68
5.56
1.9
1.9
—
—
—
0
0
28
107
2.68
5.37
1.2
1.3
—
—
—
0
0
30
120
2.57
5.27
5.4
7.1
138.4
325.9
iu/ml
—
5
18
179
1288
1.52
5.26
1.8
1.7
1.7
1.2
mg/l
0.72
138
991
133
895
1.60
5.26
3.9
2.4
2.2
2.3
g/l
1.19
125
830
47
230
2.12
5.24
2.4
3.0
8.9
10.6
g/l
1.93
34
200
139
946
1.58
5.24
1.3
1.3
42.7
36.6
iu/ml
0.17
37
294
312
2510
1.43
5.16
2.1
2.0
93.0
94.4
pmol/l
0.19
172
1290
499
4375
1.47
5.13
4.5
3.9
15.1
14.9
pmol/l
0.94
462
3909
248
1918
1.45
5.05
3.9
3.1
6.9
7.4
mmol/l
0.89
221
1576
11
23
4.84
5.02
1.4
1.3
—
—
—
0
0
108
706
1.62
4.80
2.0
1.8
—
—
—
0
0
105
683
1.63
4.75
3.5
2.8
9.8
9.1
umol/l
0.08
89
592
139
971
1.54
4.64
3.6
3.0
3.8
2.0
e6/l
0.70
69
544
205
1551
1.45
4.62
2.4
2.2
3.2
3.1
mg/l
0.21
186
1324
93
591
1.66
4.61
8.4
9.2
118.5
120.7
g/l
0.39
87
575
48
250
1.99
4.56
2.4
2.9
3.4
3.7
g/l
1.66
32
177
48
250
1.99
4.56
2.4
2.9
7.7
7.4
g/l
0.48
32
186
48
250
1.99
4.56
2.4
2.9
—
—
—
0
0
45
229
2.03
4.56
2.4
3.0
3.2
3.1
g/l
0.11
32
181
238
1856
1.42
4.54
4.7
3.3
46.0
32.2
u/l
0.66
228
1761
29
123
2.42
4.54
1.3
1.4
—
—
—
0
0
29
123
2.42
4.54
1.3
1.4
—
—
—
0
0
37
176
2.16
4.46
2.6
3.4
0.0
0.0
g/l
0.00
31
162
12
30
4.05
4.45
2.8
1.8
—
—
—
0
0
41
207
2.04
4.25
2.5
3.3
0.2
1.4
g/l
2.49
32
183
166
1224
1.46
4.24
1.9
1.7
1142.8
1180.3
nmol/l
0.27
140
920
36
173
2.14
4.24
2.6
3.4
0.0
0.0
g/l
0.00
31
161
38
187
2.09
4.22
2.5
3.4
0.0
0.0
g/l
0.50
32
173
86
549
1.64
4.20
2.9
2.5
4.5
7.1
ug/l
1.76
75
486
578
5288
1.49
4.18
5.5
4.7
2.0
2.0
mu/l
0.03
535
4758
587
5389
1.50
4.16
7.1
6.1
41.8
40.3
mmol/mol
2.62
551
4965
245
1946
1.39
4.14
4.6
4.0
23.2
9.3
mg/mmol
1.63
169
1226
49
270
1.87
3.98
6.0
6.6
1.4
1.6
%
1.24
44
257
10
24
4.21
3.90
1.1
1.0
—
—
—
0
0
118
826
1.51
3.88
37.6
24.9
1.4
1.3
inr
—
7
111
19
71
2.72
3.85
2.4
1.8
—
—
—
0
0
38
197
1.98
3.70
2.5
3.2
37.6
37.7
g/l
0.03
30
169
239
1923
1.37
3.64
3.4
3.1
2482.4
1475.6
ng/l
1.32
204
1652
65
401
1.68
3.63
7.0
8.3
24.0
24.6
mmol/l
0.52
59
379
525
4764
1.39
3.59
26.2
18.6
13.9
13.7
%
1.73
518
4671
668
6363
1.77
3.55
33.6
22.5
132.2
134.7
g/l
3.73
661
6253
159
1203
1.41
3.49
4.6
4.0
205.0
352.1
ng/l
0.90
127
975
39
209
1.92
3.47
4.1
3.1
—
—
—
0
0
75
487
1.60
3.44
6.6
3.6
130.9
85.2
ng/l
1.50
66
427
72
464
1.61
3.41
2.3
2.8
57.1
63.3
ml/min/173m2
0.56
33
196
34
175
1.99
3.39
1.2
1.9
—
—
—
0
0
166
1281
1.39
3.23
6.2
4.1
1.0
1.0
kg/l
0.26
22
191
82
553
1.55
3.21
2.7
2.0
363.1
376.0
nmol/l
0.23
74
507
30
151
2.03
3.19
2.5
2.4
191.4
194.0
%
0.05
30
146
77
513
1.56
3.18
3.9
3.6
1.2
1.2
mmol/l
0.31
70
449
15
55
2.76
3.17
1.2
1.2
64.8
54.8
u/l
—
9
38
68
441
1.60
3.15
1.9
1.7
—
—
—
0
0
63
401
1.63
3.14
4.8
3.2
122.8
126.5
g/l
0.49
63
394
29
145
2.04
3.14
2.9
2.8
30.5
32.5
umol/l
0.27
23
119
52
315
1.70
3.13
8.7
10.4
24.8
24.6
mmol/l
0.24
52
296
6
8
7.55
3.06
1.0
1.0
—
—
—
0
0
6
8
7.55
3.06
1.0
1.0
—
—
—
0
0
38
212
1.84
3.02
4.2
4.1
156.1
92.1
mg/l
0.26
32
170
38
212
1.84
3.02
4.2
4.1
36.0
46.9
mg/l
0.31
33
170
23
107
2.19
2.99
2.1
2.2
1760.5
3911.4
u/l
—
7
37
20
88
2.31
2.96
1.3
1.3
—
—
—
0
0
8
17
4.75
2.92
1.0
1.1
—
—
—
0
0
8
17
4.75
2.92
1.0
1.1
—
—
—
0
0
179
1423
1.34
2.86
2.7
2.3
—
—
—
0
0
583
5446
1.38
2.86
19.3
14.2
76.4
78.0
ml/min/173m2
0.84
505
4482
79
543
1.51
2.85
3.2
2.3
34.7
32.7
u/l
0.17
67
456
29
151
1.96
2.84
1.6
1.7
—
—
—
0
0
51
318
1.65
2.78
4.5
3.3
24.8
25.1
mmol/l
0.18
51
310
9
23
3.95
2.78
1.1
1.2
—
—
—
0
0
262
2206
1.30
2.77
5.5
4.1
—
—
—
0
0
32
175
1.87
2.72
1.7
1.6
—
—
—
0
0
16
66
2.46
2.72
1.8
1.7
—
—
—
0
0
316
2734
1.28
2.68
4.3
4.1
—
—
—
0
0
12
43
2.82
2.65
1.1
1.2
—
—
—
0
0
9
25
3.63
2.58
2.3
2.4
85.9
94.4
%
—
9
25
8
20
4.03
2.57
1.0
1.4
—
—
—
0
0
551
5129
1.33
2.56
23.6
16.5
39.0
39.5
%
0.52
353
3468
14
56
2.53
2.54
1.9
1.7
—
—
—
0
0
13
50
2.63
2.54
1.2
1.4
—
—
—
0
0
601
5670
1.38
2.53
5.4
4.7
6.1
6.0
mmol/l
0.99
556
5114
56
367
1.57
2.52
1.5
1.5
—
—
—
0
0
24
123
1.98
2.48
1.7
1.6
—
—
—
0
0
581
5461
1.34
2.44
4.7
4.1
1.3
1.3
mmol/l
0.99
539
4940
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
10
34
2.97
2.42
1.1
1.2
—
—
—
0
0
27
146
1.88
2.40
1.7
1.3
—
—
—
0
0
58
388
1.54
2.39
9.0
9.6
0.7
0.7
%
0.37
58
382
58
388
1.54
2.39
9.0
9.5
1.5
1.4
%
0.18
58
382
100
745
1.40
2.39
9.8
7.2
—
—
—
0
0
183
1495
1.30
2.38
1.6
1.6
21.3
20.5
nmol/l
0.30
161
1260
28
154
1.85
2.37
1.2
1.2
—
18.2
—
0
8
13
52
2.53
2.37
1.1
1.1
—
—
—
0
0
57
383
1.53
2.31
1.7
1.6
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
6
13
4.64
2.27
1.2
3.2
148.5
115.5
%
—
6
13
119
920
1.35
2.27
1.3
1.3
10.5
11.6
u/ml
0.07
41
339
7
18
3.92
2.25
1.0
1.2
—
—
—
0
0
5
9
5.59
2.21
1.4
2.9
—
—
—
0
0
151
1217
1.31
2.17
1.3
1.2
1.8
1.6
u/ml
0.11
39
313
56
381
1.51
2.16
5.4
3.7
1.4
1.6
mmol/l
0.21
40
287
6
14
4.31
2.15
1.3
1.4
—
—
—
0
0
189
1573
1.27
2.11
5.9
4.1
0.0
0.0
estimate
0.50
62
518
26
146
1.81
2.09
1.6
1.7
—
—
—
0
0
611
5821
1.34
2.06
5.9
5.1
2.5
2.7
mmol/l
3.86
571
5296
13
56
2.35
2.05
2.2
1.3
31.8
31.2
u/l
—
8
47
6
15
4.02
2.04
2.0
1.9
—
—
—
0
0
6
15
4.02
2.04
1.2
1.3
—
—
—
0
0
11
44
2.52
2.02
1.3
1.3
—
—
—
0
0
8
26
3.10
2.02
1.1
1.2
—
—
—
0
0
10
38
2.65
2.01
1.0
1.5
—
—
—
0
0
10
38
2.65
2.01
1.0
1.5
—
—
—
0
0
29
172
1.72
1.96
1.5
1.4
195.3
300.1
ug/g
1.72
13
98
599
5702
1.31
1.94
5.2
4.6
4.4
4.6
mmol/l
3.87
561
5229
22
122
1.83
1.86
2.6
2.6
17.3
15.9
%
—
8
61
20
108
1.88
1.83
3.1
3.5
61.1
58.3
%
0.26
20
108
35
223
1.60
1.82
1.9
1.7
—
—
—
0
0
5
12
4.19
1.82
1.0
1.0
—
—
—
0
0
7
23
3.06
1.80
1.3
1.0
—
—
—
0
0
21
116
1.83
1.80
1.1
1.2
—
1.9
—
0
12
37
241
1.56
1.77
2.3
1.9
—
—
—
0
0
6
18
3.35
1.75
1.0
1.2
—
—
—
0
0
6
18
3.35
1.75
1.0
1.1
—
—
—
0
0
9
36
2.52
1.74
5.1
3.8
—
—
—
0
0
45
308
1.49
1.73
3.4
2.6
1.2
1.2
%
0.00
45
308
593
5660
1.28
1.72
5.2
4.5
1.4
1.5
mmol/l
1.21
550
5150
17
89
1.93
1.71
1.2
1.1
—
—
—
0
0
22
126
1.77
1.69
2.2
1.2
13.1
8.6
u/l
0.45
15
96
6
19
3.18
1.66
1.2
1.0
—
—
—
0
0
8
31
2.60
1.66
2.0
2.5
—
—
—
0
0
19
105
1.83
1.64
1.5
1.6
—
—
—
0
0
85
658
1.33
1.64
3.8
3.3
—
—
—
0
0
30
190
1.60
1.62
1.3
1.3
—
—
—
0
0
71
536
1.36
1.61
3.9
3.3
281.7
220.0
ng/l
0.35
62
493
142
1179
1.26
1.61
3.0
3.1
2.5
2.5
mmol/l
0.00
129
1030
357
3256
1.19
1.57
2.8
2.8
—
—
—
0
0
57
418
1.40
1.55
2.7
2.2
10.5
12.7
nmol/l
1.23
50
362
22
133
1.67
1.44
1.3
1.1
—
—
—
0
0
18
105
1.73
1.34
1.8
1.8
—
—
—
0
0
8
34
2.37
1.29
1.1
1.3
—
—
—
0
0
12
62
1.95
1.28
3.9
2.6
—
—
—
0
0
17
102
1.68
1.17
2.9
3.3
4.7
4.4
e9/l
0.18
17
102
46
346
1.35
1.12
1.3
1.2
158.9
130.3
iu/ml
0.20
14
137
7
31
2.27
1.10
1.3
1.1
—
—
—
0
0
14
81
1.74
1.09
1.4
1.7
—
—
—
0
0
5
21
2.39
1.09
6.8
5.4
—
—
—
0
0
13
74
1.77
1.07
1.2
1.2
4.2
1.9
u/ml
—
5
20
5
22
2.28
1.03
7.6
3.9
436.0
226.7
u/l
—
5
22
5
22
2.28
1.03
1.2
1.1
244.6
190.9
iu/ml
—
5
22
5
22
2.28
1.03
2.6
1.7
20.4
59.8
ug/l
—
5
22
7
35
2.01
1.00
1.3
1.9
—
—
—
0
0
7
35
2.01
1.00
1.3
1.9
—
—
—
0
0
7
35
2.01
1.00
1.3
1.9
—
—
—
0
0
22
148
1.50
0.99
1.2
1.4
—
—
—
0
0
14
84
1.68
0.98
1.9
1.6
—
—
—
0
0
15
92
1.64
0.97
1.3
1.6
—
—
—
0
0
14
85
1.66
0.95
1.4
1.5
—
—
—
0
0
7
37
1.90
0.94
3.7
3.7
405.0
114.5
nmol/l
—
7
37
7
37
1.90
0.94
1.3
1.5
0.8
1.0
g/l
—
7
37
6
27
2.23
0.93
1.3
2.1
—
—
—
0
0
13
78
1.68
0.92
3.8
2.0
33.9
32.5
pg
1.10
13
78
6
28
2.15
0.91
1.3
2.1
—
—
—
0
0
10
56
1.80
0.88
1.2
1.4
—
—
—
0
0
14
87
1.62
0.88
1.4
1.5
—
—
—
0
0
14
87
1.62
0.88
1.4
1.5
—
—
—
0
0
14
87
1.62
0.88
1.4
1.5
—
—
—
0
0
14
87
1.62
0.88
1.4
1.5
—
—
—
0
0
43
335
1.30
0.87
1.3
1.2
412.0
248.4
u/ml
0.30
38
305
13
80
1.64
0.85
1.2
1.2
1.7
7.0
u/ml
—
6
31
14
88
1.60
0.85
1.4
1.5
—
—
—
0
0
6
31
1.94
0.84
1.7
1.3
—
—
—
0
0
6
31
1.94
0.84
1.7
1.3
—
—
—
0
0
8
45
1.79
0.84
1.6
1.7
—
—
—
0
0
24
173
1.40
0.79
2.4
1.6
—
—
—
0
0
6
33
1.82
0.79
1.7
1.3
—
—
—
0
0
148
1328
1.14
0.74
1.8
1.7
405.9
17495828.7
pmol/l
1.07
121
1086
19
133
1.44
0.74
1.5
1.3
—
—
—
0
0
19
133
1.44
0.74
2.5
2.1
134.7
127.8
g/l
0.45
12
99
7
38
1.85
0.73
1.6
1.4
—
—
—
0
0
7
38
1.85
0.73
1.6
1.4
—
—
—
0
0
31
237
1.32
0.73
3.7
4.1
1.3
1.3
mmol/l
0.18
31
228
21
152
1.39
0.70
1.9
1.4
—
—
—
0
0
5
27
1.86
0.68
1.4
2.1
—
—
—
0
0
29
373
0.77
0.68
2.0
1.9
—
—
—
0
0
5
28
1.79
0.66
1.8
1.8
—
—
—
0
0
173
1583
1.12
0.65
1.7
1.7
1.4
1.4
mmol/l
0.40
145
1307
5
29
1.73
0.64
1.8
1.8
—
—
—
0
0
21
155
1.37
0.63
1.4
1.3
39.0
28.0
iu/l
0.50
16
131
233
2174
1.11
0.61
4.7
5.2
2.4
3.2
ug/l
0.84
205
1927
0
21
0.00
0.60
0.0
1.6
—
—
—
0
0
12
80
1.51
0.60
1.7
1.7
—
—
—
0
0
22
166
1.34
0.59
1.5
1.2
—
—
—
0
0
22
166
1.34
0.59
1.5
1.2
—
—
—
0
0
6
35
1.72
0.57
1.3
1.9
—
—
—
0
0
21
159
1.33
0.56
1.9
1.8
—
—
—
0
0
12
82
1.47
0.54
1.2
1.1
—
17.6
—
0
17
67
586
1.16
0.51
1.6
1.7
1.8
1.5
%
0.66
58
497
6
41
1.47
0.50
1.0
1.1
—
—
—
0
0
6
41
1.47
0.50
1.0
1.1
—
—
—
0
0
7
45
1.56
0.49
2.1
1.3
—
—
—
0
0
7
45
1.56
0.49
2.1
1.3
—
—
—
0
0
188
1756
1.10
0.49
4.4
4.3
23.3
21.3
%
0.96
96
857
25
199
1.27
0.48
2.3
1.9
—
—
—
0
0
7
47
1.49
0.47
1.0
1.0
—
—
—
0
0
84
755
1.13
0.45
5.5
4.6
32.8
31.8
%
0.35
64
490
94
851
1.12
0.44
1.4
1.5
—
—
—
0
0
21
166
1.27
0.43
2.6
2.5
117.1
103.9
ug/min
0.10
13
96
31
258
1.21
0.42
1.5
1.3
—
—
—
0
0
10
70
1.43
0.42
9.5
3.7
—
—
—
0
0
0
18
0.00
0.40
0.0
2.8
—
—
—
0
0
9
69
1.31
0.37
1.6
1.9
—
—
—
0
0
5
37
1.35
0.37
1.8
1.7
—
—
—
0
0
9
70
1.29
0.36
1.1
1.1
—
—
—
0
0
21
256
0.81
0.36
1.0
1.0
—
—
—
0
0
6
42
1.43
0.35
1.0
1.1
—
—
—
0
0
6
42
1.43
0.35
1.0
1.1
—
—
—
0
0
6
42
1.43
0.35
1.0
1.1
—
—
—
0
0
36
415
0.86
0.35
1.9
2.0
—
—
—
0
0
36
410
0.87
0.31
1.6
1.7
—
—
—
0
0
65
711
0.91
0.30
1.4
1.4
—
—
—
0
0
17
140
1.22
0.27
1.4
1.4
—
—
—
0
0
8
64
1.25
0.27
1.5
2.0
—
—
—
0
0
9
72
1.25
0.25
1.3
1.3
—
—
—
0
0
132
1253
1.07
0.25
3.2
3.0
0.8
0.8
ug/l
0.02
89
848
11
88
1.25
0.22
1.6
1.7
—
—
—
0
0
12
146
0.82
0.22
1.5
1.6
—
—
—
0
0
72
672
1.08
0.22
3.1
4.2
4.4
29.9
ug/l
1.41
53
573
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
6.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
6
50
1.20
0.19
1.2
1.1
—
—
—
0
0
14
164
0.85
0.18
1.3
1.4
—
—
—
0
0
6
77
0.78
0.15
1.2
1.1
—
—
—
0
0
9
83
1.09
0.14
1.0
1.1
—
—
—
0
0
17
150
1.14
0.14
1.5
1.8
5822.6
17407.7
e6/l
1.56
11
113
5
60
0.83
0.08
1.4
1.6
—
—
—
0
0
15
137
1.10
0.07
1.3
1.4
—
—
—
0
0
7
81
0.86
0.07
1.4
1.7
—
—
—
0
0
7
84
0.83
0.07
1.0
1.0
—
—
—
0
0
15
138
1.09
0.06
4.4
4.0
15.4
29.1
mg/l
—
8
85
15
162
0.92
0.06
1.7
1.2
—
—
—
0
0
27
263
1.03
0.01
2.3
3.4
44.0
1528.3
u/ml
1.39
20
229
17
164
1.04
0.00
1.9
1.7
—
—
—
0
0
7
78
0.90
0.00
1.6
1.5
—
—
—
0
0
7
78
0.90
0.00
1.6
1.5
—
—
—
0
0
7
78
0.90
0.00
1.6
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
52.4
—
0
5
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
6
60
1.00
0.00
1.3
1.8
—
—
—
0
0
6
60
1.00
0.00
1.3
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
5
54
0.93
0.00
1.6
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
6
60
1.00
0.00
1.3
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint H7_OPTNERVNAS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_OPTNERVNAS | 1.359 [1.17, 1.58] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.108 |
During the follow-up period (1.1.1998 — 31.12.2019), 489 out of 1941 females with H7_OPTNERVNAS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_OPTNERVNAS | 1.46 [1.26, 1.69] | < 0.001 |
| Birth year | 0.989 [0.98, 1.0] | 0.016 |
During the follow-up period (1.1.1998 — 31.12.2019), 567 out of 1962 males with H7_OPTNERVNAS died.
Mortality risk
Mortality risk for people of age
years, who have H7_OPTNERVNAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.108% | 0.271% |
| 5 | 0.801% | 2.134% |
| 10 | 2.05% | 4.791% |
| 15 | 3.769% | 8.823% |
| 20 | 6.255% | 14.356% |
Relationships between endpoints
↥Index endpoint: H7_OPTNERVNAS – Disorders of optic nerve, not elsewhere classified
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data